Page 73 - CIBERBBN-2015-eng

Research groups
ELISHA- NMP2-CT-2003-505485, GOODFOOD- IST- 2003-508774, Conffidence-KBBE-2008-211326, CA- JAL4EU- ICT-ENIAC-2012-120215) and through con- tracts with companies. The output of this scientific activity has been reflected in an increasing number of publications (more than 160 scientific publications in high impact international journals), participation in in- ternational conferences, patents and scientific training activities performed through the supervision of doc- toral theses (more than 15 theses read) or the giving
of courses to PhD students and specialized technical personnel.
From a practical point of view, the research group is in- terested in and develops projects in the following areas
1. Cardiovascular Diseases
2. Infectious Diseases
3. Neurologic and Neurodegenerative Diseases 4. Therapeutic Drug Monitoring
5. Adverse Drug Reactions
Most relevant scientific articles
TUFA R.A., PINACHO D.G., PASCUAL N., GRANADOS M., COM- PANYO R., MARCO M.P. Development and validation of an enzyme linked immunosorbent assay for fluoroquinolo- nes in animal feeds. Food Control. 2015;57:195-201.
PASTELLS C., ACOSTA G., PASCUAL N., ALBERICIO F., ROYO M., MARCO M.-P. An immunochemical strategy based on pep- tidoglycan synthetic peptide epitopes to diagnose Staph- ylococcus aureus infections. Analytica Chimica Acta. 2015;889:203-211.
MURIANO A., CHABOTTAUX V., DISERENS J.-M., GRANIER B., SáNCHEZ-BAEZA F., MARCO M.-P. Rapid immunochemical
Highlights
Throughout 2015, the Nanobiotechnology for Diagnos- tics Group continued with its research lines, namely food safety, environmental monitoring and in keeping with the objectives of CIBER-BBN - clinical diagnosis.
We have developed an ELISA for the detection of sep- sis caused by Pseudomonas aeruginosa. The samples used were provided to us by the Microbiology Depart- ment of the University Hospital of Germans Trias i Pu- jol (HUGTiP) in collaboration with CIBER projects. With the speific immunoreagents that we produced in the group we were capable of detecting infections with this bacteria in the samples of patients with tell-tale symp- toms. In 2015, we presented our patent P201530780 in the Spanish Office for Patents and Brands. The pat- ent is titled “Compunds and their uses as haptens for the detection of Staphylococcus aureus”. This patent, along with another for the detection of Pseudomonas aeruginosa have had a lot of interest from companies and groups dedicated to point-of-care diagnosis and we
analysis of the sulfonamide-sugar conjugated fraction of antibiotic contaminated honey samples. Food Chemistry. 2015;178:156-163.
BROTO M., MATAS S., BABINGTON R., MARCO M.-P., GALVE R. Immunochemical detection of penicillins by using biohy- brid magnetic particles. Food Control. 2015;51:381-389.
AHADIAN S., YAMADA S., RAMON-AZCON J., ESTILI M., LIANG X., NAKAJIMA K. ET AL. Hybrid hydrogel-aligned carbon nanotube scaffolds to enhance cardiac differentiation of embryoid bodies. Acta Biomaterialia. 2015.
are currently in negotiations with several companies for the possibility to exploit them.
Since 2011 we have been collaborating with an Amer- ican company in the development of immunoreagents for the detection of neurodegenerative disease bio- markers and in 2015 we extended this agreement to include two new lines of investigation - the preparation of oxidised cardiolipines and the detection and quanti- fication of pterins.
We are developing and validating immunoreagents for the detection of citotoxic agents such as fluoracil and cyclophosphamide for the therapeutic monitoring of these drugs in treated pacients.
We now have a catalogue of the principal biomarkers involved in cardiovascular diseases and we are optimis- ing the conditions to create a multiplexed system that can recognise various biomarkers together.
Institution: Agencia Estatal Consejo Superior de Investigaciones Científicas
Contact: Instituto de Química Avanzada de Cataluña · C/ Jordi Girona, 18-26 08034 Barcelona E.mail: [email protected] · Website: http://www.iqac.csic.es/nb4d
CIBER-BBN I Annual report 2015 I 73